Advertisement

Current Medical Science

, Volume 39, Issue 1, pp 28–36 | Cite as

Role of Wnt/β-Catenin Pathway in the Arterial Medial Calcification and Its Effect on the OPG/RANKL System

  • Bin Nie
  • Shao-ying ZhangEmail author
  • Si-ming GuanEmail author
  • Shao-qiong Zhou
  • Xin Fang
Article
  • 14 Downloads

Abstract

In this study, the hypothesis that Wnt/β-catenin pathway is involved in the arterial calcification by regulating the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL) system was tested. The β-catenin expression was measured in the warfarin-induced calcified arteries and the osteoblast-like cells differentiating from smooth muscle cells (SMCs) by immunohistochemistry and Western blotting. The Wnt/β-catenin pathway was activated or inhibited by lithium chloride (LiCl) or dickkopf 1 (DKK1) in vitro and in vivo. Then the calcification level was determined by von Kossa staining, Ca2+ content assay, and alkaline phosphatase (ALP) activity assay. The expression levels of osteocalcin, OPG and RANKL were detected by Western blotting or real-time PCR. The results showed that in calcified arteries and OBL cells, the activation of Wnt/β-catenin pathway significantly enhanced the calcification as evidenced by increased von Kossa stains, Ca2+ contents, ALP activities, and osteocalcin expression levels (P<0.05), and it promoted the RANKL expression (P<0.05), but slightly affected the OPG expression. These results indicated that the activation of Wnt/β-catenin pathway worsens the arterial calcification, probably by promoting the RANKL expression.

Key words

arterial calcification Wnt/β-catenin pathway osteoprotegerin receptor activator of NF-κB ligand 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rennenberg RJ, Schurgers LJ, Kroon AA, et al. Arterial calcifications. J Cell Mol Med, 2010,14(9):2203–2210CrossRefGoogle Scholar
  2. 2.
    Valdivielso JM. Vascular calcification: types and mechanisms. Nefrologia, 2011,31(2):142–147Google Scholar
  3. 3.
    Tsushima M. Aortic calcification and calcium. Clin Calcium, 2010,20(11):1627–1635Google Scholar
  4. 4.
    Harper E, Forde H, Davenport C, et al. Vascular calcification in type–2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. Vascul Pharmacol, 2016,7(82):30–40CrossRefGoogle Scholar
  5. 5.
    Neven E, De Schutter TM, De Broe ME, et al. Cell biological and physicochemical aspects of arterial calcification. Kidney Int, 2011,79(11):1166–1177CrossRefGoogle Scholar
  6. 6.
    Leopold JA. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med, 2015,25(4):267–274CrossRefGoogle Scholar
  7. 7.
    Ogawa T, Nitta K. Pathogenesis and Management of Vascular Calcification in Patients with End–Stage Renal Disease. Contrib Nephrol, 2018,196:71–77CrossRefGoogle Scholar
  8. 8.
    Bardeesi ASA, Gao J, Zhang K, et al. A novel role of cellular interactions in vascular calcification. J Transl Med, 2017,15(1):95CrossRefGoogle Scholar
  9. 9.
    Nusse R, Clevers H. Wnt/ß–Catenin signaling, disease, and emerging therapeutic modalities. Cell, 2017,169(6):985–999CrossRefGoogle Scholar
  10. 10.
    Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/ beta–catenin signaling is required for normal bone homeostasis. Mol Cell Biol, 2010,30(12):3071–3085CrossRefGoogle Scholar
  11. 11.
    Kubota T, Michigami T, Ozono K. Wnt signaling in bone metabolism. J Bone Miner Metab, 2009,27(3):265–271CrossRefGoogle Scholar
  12. 12.
    Trouvin AP, Goëb V. Receptor activator of nuclear factor–?B ligand and osteoprotegerin: maintaining the balance to prevent bone loss, Clin Interv Aging, 2010,19(5):345–354Google Scholar
  13. 13.
    Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep, 2007,5(3):98–104CrossRefGoogle Scholar
  14. 14.
    D’Amelio P, Isaia G, Isaia GC. The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest, 2009,32(4):6–9Google Scholar
  15. 15.
    Shen C, Yuan Y, Li F, et al. Mechanism of genistein regulating the differentiation of vascular smooth muscle cells into osteoblasts via the OPG/RANKL pathway. Oncotarget, 2017,8(44):76857–76864Google Scholar
  16. 16.
    Xie H, Xie PL, Wu XP, et al. Omentin–1 attenuates arterial calcification and bone loss in osteoprotegerindeficient mice by inhibition of RANKL expression. Cardiovasc Res, 2011,92(2):296–306CrossRefGoogle Scholar
  17. 17.
    Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF–kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol, 2009,175(2):473–478CrossRefGoogle Scholar
  18. 18.
    Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis, 2009, 204(2):321–329CrossRefGoogle Scholar
  19. 19.
    Schoppet M, Kavurma MM, Hofbauer LC, et al. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochem Biophys Res Commun, 2011,407(1):103–107CrossRefGoogle Scholar
  20. 20.
    Liu C, Wan J, Yang Q, et al. Effects of atorvastatin on warfarin–induced aortic medial calcification and systolic blood pressure in rats. J Huazhong Univ Sci Technolog Med Sci, 2008,28(5):535–538CrossRefGoogle Scholar
  21. 21.
    Clément–Lacroix P, Ai M, Morvan F, et al. Lrp5–independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci USA, 2005,102(48):17406–17411CrossRefGoogle Scholar
  22. 22.
    Castellot J, Favreau LV, Karnovsky MJ, et al. Inhibition of vascular smooth muscle cell growth by endothelial cell–derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem, 1982,257(19):11256–11260Google Scholar
  23. 23.
    Olesen P, Nguyen K, Wogensen L, et al. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high–dose insulin. Am J Physiol Heart Circ Physiol, 2007,292(2):1058–1064CrossRefGoogle Scholar
  24. 24.
    Heo JS, Lee SY, Lee JC. Wnt/ß–catenin signaling enhances osteoblastogenic differentiation from human periodontal ligament fibroblasts. Mol Cells, 2010,30(5): 449–454CrossRefGoogle Scholar
  25. 25.
    Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol, 2014,34(4):715–723CrossRefGoogle Scholar
  26. 26.
    Eijken M, Meijer IM, Westbroek I, et al. Wnt signaling acts and is regulated in a human osteoblast differentiation dependent manner. J Cell Biochem, 2008,104(2):568–579CrossRefGoogle Scholar
  27. 27.
    Li X, Liu P, Liu W, et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet, 2005,37(9):945–952CrossRefGoogle Scholar
  28. 28.
    Osako MK, Nakagami H, Koibuchi N, et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res, 2010,107(4):466–475CrossRefGoogle Scholar
  29. 29.
    Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK–BMP4–dependent pathway. Circ Res, 2009,104(9):1041–1048CrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology 2019

Authors and Affiliations

  1. 1.Department of Geriatrics, the Central Hospital of Wuhan, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Geriatrics, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations